There is growing evidence suggesting that PPARγ can inhibit microglial activation, promote M2 polarization, and suppress inflammatory cytokines in inflammation‐related diseases, such as MS, EAE, Parkinson's disease (PD), stroke, and major depressive disorder (MDD) (Han et al., 2015; Kaiser et al., 2009; Mandrekar‐Colucci, Karlo & Landreth, 2012; Orihuela et al., 2016; Zhao et al., 2016). This evidence concerns the gene PPARG and myeloid sarcoma.